In an in vitro trial combining treatment with CAR-NK-92 and anti-PD-L1 monoclonal antibody, atezolizumab enhanced the anti-tumor effect of CAR NK-92 by directly acting on PD-L1 on CAR NK-92 and by blocking PD-L1/PD-1 axis, releasing CD8+ T cells, effectively improving the anti-CRPC efficacy (190). Here, CD274 is linked to neoplasm.